{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:47:52Z","timestamp":1785527272602,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008132","name":"Universidade Federal De Pernambuco","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008132","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Schistosomiasis is an acute and chronic illness caused by parasites of the genus\n                    <jats:italic>Schistosoma<\/jats:italic>\n                    . It is present in 79 countries worldwide and primarily affects socioeconomically vulnerable populations due to exposure to infested water during daily activities. Praziquantel is the primary drug used in international schistosomiasis treatment. However, adverse effects and parasite resistance mechanisms have been reported, ranging from experimentally induced resistance to naturally occurring resistance in real-world populations. New therapeutic targets have been identified to address these issues. Consequently, drug repurposing is often considered a faster alternative that may offer lower development risks and potentially fewer adverse outcomes than newly synthesized drugs.\u00a0Building on this potential, this study aimed to identify drug repurposing candidates as alternatives for schistosomiasis treatment through a systematic review. Two databases (ScienceDirect and PubMed) were searched. The selection of studies and writing of this systematic review followed the PRISMA guidelines.\u00a0Of the 313 articles identified, 28 were selected after applying the exclusion criteria. The best results observed were celecoxib (over 90% for egg burden and parasite load), mefenamic acid (92% for parasite load and 82% for egg burden), and chlorambucil (75% parasite load and 85% egg burden).\u00a0This review highlights the data supporting this strategy as a viable alternative for developing new therapies for schistosomiasis. As these compounds have been used clinically for a long time, substantial preclinical, biosafety, and pharmacovigilance data are already available. Their adverse effects and toxicities are well characterized, which may contribute to a reduction in overall costs and development timelines, although robust clinical validation remains a prerequisite for their use.\n                  <\/jats:p>","DOI":"10.1007\/s00210-026-05729-4","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:21:04Z","timestamp":1785205264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping therapeutic alternatives: a systematic review of preclinical drug repurposing for schistosomiasis"],"prefix":"10.1007","author":[{"given":"Bruna Cristiane Souza","family":"Fran\u00e7a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demis Ferreira","family":"de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Amadeu Gonzaga","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lavinya Arruda","family":"da Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir Veloso","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Joanellys dos","family":"Santos Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laysa Creusa Paes Barreto Barros","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Jos\u00e9","family":"Rolim Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"5729_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2147\/IJN.S389449","volume":"18","author":"WE Abd El Hady","year":"2023","unstructured":"Abd El Hady WE et al (2023) The idiosyncratic efficacy of spironolactone-loaded PLGA nanoparticles against murine intestinal schistosomiasis. International Journal of Nanomedicine 18:987\u20131005. https:\/\/doi.org\/10.2147\/IJN.S389449","journal-title":"International Journal of Nanomedicine"},{"key":"5729_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2021.105891","volume":"218","author":"IF Abou-El-Naga","year":"2021","unstructured":"Abou-El-Naga IF et al (2021) Effect of celecoxib against different developmental stages of experimental Schistosoma mansoni infection. Acta Trop 218:105891. https:\/\/doi.org\/10.1016\/j.actatropica.2021.105891","journal-title":"Acta Trop"},{"key":"5729_CR3","doi-asserted-by":"publisher","unstructured":"Adel Madbouly N et al (2022) \u201cIn vitro and in vivo impacts of nifedipine and diltiazem on praziquantel chemotherapy in murine Schistosoma mansoni.\u201d Exp Parasitol 236\u2013237:108256. https:\/\/doi.org\/10.1016\/j.exppara.2022.108256","DOI":"10.1016\/j.exppara.2022.108256"},{"key":"5729_CR4","unstructured":"Amjad MT, Chidharla A, Kasi A (2023) Cancer chemotherapy. StatPearls Publishing, Treasure Island (FL). Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564367\/. Accessed 17 Feb 2026"},{"issue":"1","key":"5729_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s44337-025-00293-x","volume":"2","author":"H Banda","year":"2025","unstructured":"Banda H, Abere A (2025) Determining the mechanisms of praziquantel resistance in schistosomiasis: insights and future directions. Discov Med 2(1):105. https:\/\/doi.org\/10.1007\/s44337-025-00293-x","journal-title":"Discov Med"},{"key":"5729_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2019.107793","volume":"208","author":"SS Botros","year":"2020","unstructured":"Botros SS et al (2020) The phosphodiesterase-4 inhibitor roflumilast impacts Schistosoma mansoni ovipositing in vitro but displays only modest antischistosomal activity in vivo. Experimental Parasitology 208:107793. https:\/\/doi.org\/10.1016\/j.exppara.2019.107793","journal-title":"Experimental Parasitology"},{"issue":"7","key":"5729_CR7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.ijpara.2005.02.005","volume":"35","author":"S Botros","year":"2005","unstructured":"Botros S et al (2005) Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. Int J Parasitol 35(7):787\u2013791. https:\/\/doi.org\/10.1016\/j.ijpara.2005.02.005","journal-title":"Int J Parasitol"},{"key":"5729_CR8","unstructured":"Campbell S, Soman-Faulkner K (2023) Antiparasitic Drugs. StatPearls. Treasure Island (FL): StatPearls Publishing. Dispon\u00edvel em: nih.gov"},{"key":"5729_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-015-1023-y","author":"N Cowan","year":"2015","unstructured":"Cowan N, Keiser J (2015) Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni. Parasit Vectors. https:\/\/doi.org\/10.1186\/s13071-015-1023-y","journal-title":"Parasit Vectors"},{"key":"5729_CR10","doi-asserted-by":"publisher","unstructured":"Siqueira LDP et al (2017) \u201cSchistosomiasis: drugs used and treatment strategies.\u201d Acta Tropica176:179\u2013187.https:\/\/doi.org\/10.1016\/j.actatropica.2017.08.002","DOI":"10.1016\/j.actatropica.2017.08.002"},{"key":"5729_CR11","doi-asserted-by":"publisher","unstructured":"Lopes MD et al (2025) Impact of combination chemotherapy with praziquantel and gentamicin or doxycycline on acute hepatic and intestinal schistosomiasis in BALB\/c mice. Exp Parasitol 271:108928.  https:\/\/doi.org\/10.1016\/j.exppara.2025.108928","DOI":"10.1016\/j.exppara.2025.108928"},{"key":"5729_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fpara.2024.1471451","author":"G Eastham","year":"2024","unstructured":"Eastham G et al (2024) Praziquantel resistance in schistosomes: a brief report. Front Parasitol. https:\/\/doi.org\/10.3389\/fpara.2024.1471451","journal-title":"Front Parasitol"},{"key":"5729_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.actatropica.2016.11.006","volume":"166","author":"MM Eissa","year":"2017","unstructured":"Eissa MM et al (2017) Repositioning of chlorambucil as a potential anti-schistosomal agent. Acta Tropica 166:58\u201366. https:\/\/doi.org\/10.1016\/j.actatropica.2016.11.006","journal-title":"Acta Tropica"},{"key":"5729_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2020.105714","volume":"212","author":"MM Eissa","year":"2020","unstructured":"Eissa MM et al (2020a) Evaluation of prophylactic efficacy and safety of praziquantel-miltefosine nanocombination in experimental Schistosomiasis mansoni. Acta Tropica 212:105714. https:\/\/doi.org\/10.1016\/j.actatropica.2020.105714","journal-title":"Acta Tropica"},{"key":"5729_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-020-04346-1","author":"MM Eissa","year":"2020","unstructured":"Eissa MM et al (2020) Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni. Parasit Vectors. https:\/\/doi.org\/10.1186\/s13071-020-04346-1","journal-title":"Parasit Vectors"},{"issue":"04","key":"5729_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1017\/s0022149x18000421","volume":"93","author":"SN El-Beshbishi","year":"2018","unstructured":"El-Beshbishi SN et al (2018) Efficacy of artemisinin\u2013naphthoquine phosphate against Schistosoma haematobium adult flukes: dose\u2013effect relationship and tegumental alterations. J Helminthol 93(04):513\u2013518. https:\/\/doi.org\/10.1017\/s0022149x18000421","journal-title":"J Helminthol"},{"key":"5729_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.actatropica.2016.03.038","volume":"159","author":"RM El-Moslemany","year":"2016","unstructured":"El-Moslemany RM et al (2016) Miltefosine lipid nanocapsules: intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni. Acta Trop 159:142\u2013148. https:\/\/doi.org\/10.1016\/j.actatropica.2016.03.038","journal-title":"Acta Trop"},{"key":"5729_CR18","unstructured":"Farzam K, Sabir S, O\u2019Rourke MC (2025) Antihistamines. StatPearls Publishing, Treasure Island (FL). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538188\/. Accessed 17 June  2026"},{"key":"5729_CR19","unstructured":"Ghlichloo I, Gerriets V (2022) Nonsteroidal anti-inflammatory drugs (NSAIDs). StatPearls Publishing, Treasure Island (FL). https:\/\/pubmed.ncbi.nlm.nih.gov\/31613522\/. Accessed 17 June 2026"},{"key":"5729_CR20","doi-asserted-by":"publisher","unstructured":"Girgin AB, Duman E (2025) Is a combination of diosmin and hesperidin effective on swelling, pain, and range of motion after total knee arthroplasty? J Arthroplasty [Preprint]. https:\/\/doi.org\/10.1016\/j.arth.2025.10.058","DOI":"10.1016\/j.arth.2025.10.058"},{"issue":"2","key":"5729_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/biom9020054","volume":"9","author":"MJ Gouveia","year":"2019","unstructured":"Gouveia MJ et al (2019) Combination anthelmintic\/antioxidant activity against Schistosoma mansoni. Biomolecules 9(2):54. https:\/\/doi.org\/10.3390\/biom9020054","journal-title":"Biomolecules"},{"key":"5729_CR22","unstructured":"Grando RL, Claudia A, Fierro IM (2020) \u201cO reposicionamento de f\u00e1rmacos como uma potencial estrat\u00e9gia para o tratamento da COVID-19,\u201d Fiocruz.br [Preprint]. Available at:  http:\/\/observatorio.fiocruz.br\/estudos\/o-reposicionamento-de-farmacos-como-uma-potencial-estrategia-para-o-tratamento-da-covid-19. Accessed Dec 2025"},{"key":"5729_CR23","doi-asserted-by":"publisher","unstructured":"Guerra RA et al (2019) In vitro and in vivo studies of spironolactone as an antischistosomal drug capable of clinical repurposing. Antimicrob Agents Chemother 63(3):e01722\u201318. https:\/\/doi.org\/10.1128\/AAC.01722-18","DOI":"10.1128\/AAC.01722-18"},{"key":"5729_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104067","volume":"102","author":"A Guidi","year":"2020","unstructured":"Guidi A et al (2020) (+)-(R)- and (\u2212)-(S)-Perhexiline maleate: Enantioselective synthesis and functional studies on Schistosoma mansoni larval and adult stages. Bioorganic Chemistry 102:104067. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104067","journal-title":"Bioorganic Chemistry"},{"issue":"3","key":"5729_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/pim.13030","volume":"46","author":"MA Hasby Saad","year":"2024","unstructured":"Hasby Saad MA et al (2024) Potential i-Nos\/Arg-1 switch with NLRP3 and parasitic load down regulation in experimental Schistosoma mansoni infection via chloroquine repurposing. Parasite Immunol 46(3):e13030. https:\/\/doi.org\/10.1111\/pim.13030","journal-title":"Parasite Immunol"},{"key":"5729_CR26","unstructured":"Hermiz C, Sedhai YR (2023) Angina. Treasure Island (FL): StatPearls Publishing. Available at:  http:\/\/scholar.google.com\/scholar_lookup?&title=Angina&publication_year=2024&author=Hermiz%2CC&author=Sedhai%2CYR. Accessed 17 June 2026"},{"key":"5729_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2022.106342","volume":"229","author":"EI Ibrahim","year":"2022","unstructured":"Ibrahim EI et al (2022) A single oral dose of celecoxib-loaded solid lipid nanoparticles for treatment of different developmental stages of experimental schistosomiasis mansoni. Acta Tropica 229:106342. https:\/\/doi.org\/10.1016\/j.actatropica.2022.106342","journal-title":"Acta Tropica"},{"issue":"1","key":"5729_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1473-3099(21)00090-6","volume":"22","author":"C Kokaliaris","year":"2022","unstructured":"Kokaliaris C et al (2022) Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study. Lancet Infect Dis 22(1):136\u2013149. https:\/\/doi.org\/10.1016\/S1473-3099(21)00090-6","journal-title":"Lancet Infect Dis"},{"key":"5729_CR29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ebiom.2019.04.029","volume":"43","author":"EM Lago","year":"2019","unstructured":"Lago EM et al (2019) Phenotypic screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the treatment of schistosomiasis. EBioMedicine 43:370\u2013379. https:\/\/doi.org\/10.1016\/j.ebiom.2019.04.029","journal-title":"EBioMedicine"},{"issue":"17","key":"5729_CR30","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1161\/circulationaha.118.035455","volume":"138","author":"M Lei","year":"2018","unstructured":"Lei M et al (2018) Modernized classification of cardiac antiarrhythmic drugs. Circulation 138(17):1879\u20131896. https:\/\/doi.org\/10.1161\/circulationaha.118.035455","journal-title":"Circulation"},{"key":"5729_CR31","doi-asserted-by":"publisher","unstructured":"Martinez-Zapata MJ et al (2020) \u201cPhlebotonics for venous insufficiency\u201d. Cochrane Database Syst Revi 2020(11). https:\/\/doi.org\/10.1002\/14651858.CD003229.pub4","DOI":"10.1002\/14651858.CD003229.pub4"},{"issue":"8","key":"5729_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000504","volume":"3","author":"SD Melman","year":"2009","unstructured":"Melman SD et al (2009) Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Neglected Tropical Diseases 3(8):e504. https:\/\/doi.org\/10.1371\/journal.pntd.0000504","journal-title":"PLoS Neglected Tropical Diseases"},{"issue":"5","key":"5729_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-024-08236-8","volume":"123","author":"OS Mohammad","year":"2024","unstructured":"Mohammad OS et al (2024) Therapeutic efficacy of candidate antischistosomal drugs in a murine model of schistosomiasis mansoni. Parasitol Res 123(5):215. https:\/\/doi.org\/10.1007\/s00436-024-08236-8","journal-title":"Parasitol Res"},{"key":"5729_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.hipert.2024.03.004","author":"FJ Morales-Olivas","year":"2024","unstructured":"Morales-Olivas FJ (2024) Diuretics use in the management of hypertension. Hipertens Riesgo Vasc. https:\/\/doi.org\/10.1016\/j.hipert.2024.03.004","journal-title":"Hipertens Riesgo Vasc"},{"key":"5729_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.actatropica.2014.12.005","volume":"143","author":"SF Mossallam","year":"2015","unstructured":"Mossallam SF, Amer EI, El-Faham MH (2015) Efficacy of Synriam\u2122, a new antimalarial combination of OZ277 and piperaquine, against different developmental stages of Schistosoma mansoni. Acta Tropica 143:36\u201346. https:\/\/doi.org\/10.1016\/j.actatropica.2014.12.005","journal-title":"Acta Tropica"},{"key":"5729_CR36","unstructured":"National Cancer Institute (2021) What is cancer? Available at:  https:\/\/www.cancer.gov\/about-cancer\/understanding\/what-is-cancer.  Accessed 17 Dec 2025"},{"issue":"5","key":"5729_CR37","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00436-019-06259-0","volume":"118","author":"RN Oliveira","year":"2019","unstructured":"Oliveira RN et al (2019) In vitro schistosomicidal activity of tamoxifen and its effectiveness in a murine model of schistosomiasis at a single dose. Parasitol Res 118(5):1625\u20131631. https:\/\/doi.org\/10.1007\/s00436-019-06259-0","journal-title":"Parasitol Res"},{"key":"5729_CR38","unstructured":"Pan American Health Organization (PAHO) (2024) Schistosomiasi. https:\/\/www.paho.org\/pt\/node\/4940"},{"key":"5729_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M et al (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"5729_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"5729_CR41","doi-asserted-by":"publisher","unstructured":"Panic G et al (2015) \u201cActivity profile of an FDA-approved compound library against Schistosoma mansoni\u201d. PLOS Negl Trop Dis9(7):e0003962.  https:\/\/doi.org\/10.1371\/journal.pntd.0003962. Edited by C. Cunningham","DOI":"10.1371\/journal.pntd.0003962"},{"key":"5729_CR42","doi-asserted-by":"publisher","unstructured":"Poroikov V, Druzhilovskiy D (2019) \u201cDrug repositioning: new opportunities for older drugs.\u201d Elsevier eBooks, pp 3\u201317. https:\/\/doi.org\/10.1016\/b978-0-12-816125-8.00001-8","DOI":"10.1016\/b978-0-12-816125-8.00001-8"},{"issue":"7","key":"5729_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ph14070686","volume":"14","author":"R Porto","year":"2021","unstructured":"Porto R et al (2021) Antiparasitic properties of cardiovascular agents against human intravascular parasite Schistosoma mansoni. Pharmaceuticals (Basel, Switzerland) 14(7):686. https:\/\/doi.org\/10.3390\/ph14070686","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"5729_CR44","doi-asserted-by":"publisher","unstructured":"Roquini DB et al (2019) \u201cPromethazine exhibits antiparasitic properties in vitro and reduces worm burden, egg production, hepatomegaly, and splenomegaly in a schistosomiasis animal model\u201d. 63(12). https:\/\/doi.org\/10.1128\/aac.01208-19","DOI":"10.1128\/aac.01208-19"},{"issue":"4","key":"5729_CR45","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01393-23","volume":"11","author":"V Roquini","year":"2023","unstructured":"Roquini V et al (2023) The existing drug nifuroxazide as an antischistosomal agent: in vitro, in vivo, and in silico studies of macromolecular targets. Microbiol Spectr 11(4):e01393-23. https:\/\/doi.org\/10.1128\/spectrum.01393-23","journal-title":"Microbiol Spectr"},{"issue":"2","key":"5729_CR46","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.toxlet.2009.05.013","volume":"189","author":"K Schneider","year":"2009","unstructured":"Schneider, K. et al. (2009) \u201c\u2018ToxRTool\u2019, a new tool to assess the reliability of toxicological data\u201d, Toxicology Letters, 189(2), pp. 138\u2013144. Available at: doi: 10.1016\/j.toxlet.2009.05.013.https:\/\/doi.org\/10.1016\/j.toxlet.2009.05.013","journal-title":"Toxicology Letters"},{"issue":"6","key":"5729_CR47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.15445","volume":"7","author":"A Sertkaya","year":"2024","unstructured":"Sertkaya A et al (2024) Costs of drug development and research and development intensity in the US, 2000\u20132018. JAMA Network Open 7(6):e2415445. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.15445","journal-title":"JAMA Network Open"},{"key":"5729_CR48","doi-asserted-by":"publisher","unstructured":"Silva TC et al (2021) New evidence for tamoxifen as an antischistosomal agent: in vitro, in vivo and target fishing studies. Future Med Chem 13(11):945-957. https:\/\/doi.org\/10.4155\/fmc-2020-0311","DOI":"10.4155\/fmc-2020-0311"},{"issue":"12","key":"5729_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-024-08418-4","volume":"123","author":"NE Skhawy","year":"2024","unstructured":"Skhawy NE et al (2024) Potential anti-schistosomal effect of Daflon, a repurposed drug targeting different stages of schistosome maturity. Parasitol Res 123(12):402. https:\/\/doi.org\/10.1007\/s00436-024-08418-4","journal-title":"Parasitol Res"},{"key":"5729_CR50","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02582-16","author":"N Vale","year":"2017","unstructured":"Vale N et al (2017) Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02582-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"5729_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009432","volume":"15","author":"N Vejzagi\u0107","year":"2021","unstructured":"Vejzagi\u0107 N et al (2021) Identification of hit compounds with anti-schistosomal activity on in vitro generated juvenile worms in cell-free medium. PLoS Negl Trop Dis 15(5):e0009432. https:\/\/doi.org\/10.1371\/journal.pntd.0009432","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"5729_CR52","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/14656566.2024.2333372","volume":"25","author":"MA Villamizar-Monsalve","year":"2024","unstructured":"Villamizar-Monsalve MA et al (2024) Current drug strategies for the treatment and control of schistosomiasis. Expert Opin Pharmacother 25(4):409\u2013420. https:\/\/doi.org\/10.1080\/14656566.2024.2333372","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"5729_CR53","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40249-018-0444-1","volume":"7","author":"H-B Weng","year":"2018","unstructured":"Weng H-B, Chen H-X, Wang M-W (2018) Innovation in neglected tropical disease drug discovery and development. Infect Dis Poverty 7(1):67. https:\/\/doi.org\/10.1186\/s40249-018-0444-1","journal-title":"Infect Dis Poverty"},{"key":"5729_CR54","unstructured":"World Health Organization (2026) Schistosomiasis (Bilharzia). Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schistosomiasis . Accessed 21 June 2026"},{"key":"5729_CR55","doi-asserted-by":"publisher","unstructured":"Xavier RP et al (2020) \u201cH1-antihistamines as antischistosomal drugs: in vitro and in vivo studies\u201d. Parasit Vectors 13(1). https:\/\/doi.org\/10.1186\/s13071-020-04140-z","DOI":"10.1186\/s13071-020-04140-z"},{"issue":"1","key":"5729_CR56","doi-asserted-by":"publisher","first-page":"e0012735","DOI":"10.1371\/journal.pntd.0012735","volume":"19","author":"H Zhang","year":"2025","unstructured":"Zhang H et al (2025) Progress in antileishmanial drugs: mechanisms, challenges, and prospects. PLoS Negl Trop Dis 19(1):e0012735\u2013e0012735. https:\/\/doi.org\/10.1371\/journal.pntd.0012735","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"5729_CR57","doi-asserted-by":"publisher","first-page":"e1011498","DOI":"10.1371\/journal.ppat.1011498","volume":"19","author":"P Zhu","year":"2023","unstructured":"Zhu P et al (2023) Advances in new target molecules against schistosomiasis: a comprehensive discussion of physiological structure and nutrient intake. PLoS Pathog 19(7):e1011498\u2013e1011498. https:\/\/doi.org\/10.1371\/journal.ppat.1011498","journal-title":"PLoS Pathog"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05729-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05729-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05729-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:10:50Z","timestamp":1785521450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05729-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":57,"alternative-id":["5729"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05729-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study is a systematic review of published literature and does not involve direct experimentation with human or animal subjects by the authors.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PRISMA guidelines and methodology were followed. The PRISMA checklist is available as Supplementary material.","order":3,"name":"Ethics","label":"Standard for reporting","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}